Pharmaceuticals

Agenus is a Speculative Trade Worth the Risk

August 31, 2021 by Rick Rouse

Angenus (AGEN) is a biotech company focused on clinical-stage immuno-oncology, with 17 candidates in development. Nine of those candidates are company owned, while the rest are with partnerships of some well-known drug makers. AGEN also has three experimental vaccines in clinical studies, as well as two adjuvants, which are substances that enhance the body’s immune […]

Continue Reading →

Rite Aid Remains a Risky Investment

August 24, 2021 by Rick Rouse

Shares of Rite Aid (RAD) came into 2021 on a roll after rising from a 52-week low of $8.86 to hit a 52-week peak of $32.48 in late January. Some of the bullishness here was the result of Rite Aid being a so-called “meme stock” that Reddit traders had on their radar. Other meme stocks […]

Continue Reading →

Trade of the Week: PFE

July 31, 2021 by Jay Soloff

There was a significant amount of unusual options action this past week in Pfizer (PFE). The pharmaceutical giant posted earnings during the week, which resulted in over 12x the numbers of average options traded on the day of the release. More impressively, 94% of the action was in calls, which is generally a very bullish […]

Continue Reading →

New COVID-19 “Papers” Could Determine Who Can and Cannot Enter Buildings

September 2, 2020 by Tim Plaehn

Last week there was a COVID-19 testing announcement with the potential to let United States citizens and the U.S. economy more quickly return to some semblance of normalcy. The availability of a $5.00, 15-minute COVID test will let life return to a more historical level of activity. On Wednesday, August 26, Abbott (ABT) announced it […]

Continue Reading →

Information contained in this email and websites maintained by Magnifi Communities LLC are provided for educational purposes only and are neither an offer nor a recommendation to buy or sell any security, options on equities, or cryptocurrency. Magnifi Communities LLC and its affiliates may hold a position in any of the companies mentioned. Magnifi Communities LLC is neither a registered investment adviser nor a broker-dealer and does not provide customized or personalized recommendations. Any one-on-one coaching or similar products or services offered by or through Magnifi Communities LLC does not provide or constitute personal advice, does not take into consideration and is not based on the unique or specific needs, objectives or financial circumstances of any person, and is intended for education purposes only. Past performance is not necessarily indicative of future results. No trading strategy is risk free. Trading and investing involve substantial risk, and you may lose the entire amount of your principal investment or more. You should trade or invest only “risk capital” - money you can afford to lose. Trading and investing is not appropriate for everyone. We urge you to conduct your own research and due diligence and obtain professional advice from your personal financial adviser or investment broker before making any investment decision.

Investors Alley, a division of TIFIN Group LLC, is affiliated with Magnifi via common ownership. Investors Alley will receive cash compensation for referrals of clients who open accounts with Magnifi.

Magnifi LLC does not charge advisory fees or transaction fees for non-managed accounts. Clients who elect to have Magnifi LLC manage all or a portion of their account will be charged an advisory fee. Magnifi LLC receives compensation from product sponsors related to recommendations. Other fees and charges may apply.

Diversification does not guarantee a profit or protect against a loss in a declining market. It is a method used to help manage investment risk.

Mutual Funds and Exchange Traded Funds (ETFs) are sold by prospectus. Please consider the investment objectives, risks, charges, and expenses carefully before investing. The prospectus, which contains this and other information about the investment company, can be obtained from the Fund Company or your financial professional. Be sure to read the prospectus carefully before deciding whether to invest.